LTA and Hepatic fibrosis: Compared with the GDM group, mRNA levels of COL1 A1, ATAC2, TNF-β, and PDGF in the ω-3 FAs treatment group showed a significant decrease (Figure 4k–n), suggesting that the treatment with ω-3 FAs may effectively inhibit the occurrence of liver fibrosis.